Vanda Pharmaceuticals placed its VQW-765 social anxiety disorder program on hold following the Phase 3 trial failure announced on October 14, 2026

From the articleVanda says anxiety drug failed main goal of late-stage study, puts program on hold | ReutersAlso in Vanda’s social anxiety drug flunks Phase 3 trial in female patients